Form 4: Pacira BioSciences Director Michael J. Yang Reports Significant Equity Grant

Pacira BioSciences, Inc. Director Michael J. Yang has reported the acquisition of 6,163 restricted stock units and 11,279 stock options as part of a compensation grant on June 11, 2025.

Summary

• Michael J. Yang, a Director of Pacira BioSciences, Inc. (PCRX), reported changes in his beneficial ownership via a Form 4 filing.
• On June 11, 2025, Mr. Yang acquired 6,163 shares of common stock in the form of restricted stock units (RSUs).
• These RSUs vest on June 11, 2026, contingent upon his continuous service with the company, with each RSU representing the contingent right to receive one share of the issuer's common stock.
• Additionally, Mr. Yang acquired 11,279 stock options with an exercise price of $24.34.
• These stock options also vest and become exercisable on June 11, 2026, provided he remains in continuous service, and have an expiration date of June 11, 2035.
• Following these transactions, Mr. Yang beneficially owns 13,393 shares of common stock directly and 11,279 stock options directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects a standard equity compensation grant to a director, which aligns management's interests with shareholders and incentivizes long-term service. It is a routine filing and does not indicate any operational or financial changes.

Positives

• Grant of 6,163 restricted stock units (RSUs) to Director Michael J. Yang, aligning his interests with shareholders.
• Grant of 11,279 stock options with an exercise price of $24.34 to Director Michael J. Yang, providing further incentive for long-term performance and retention.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged and transparent equity compensation strategy.

Risks

• The vesting of both the 6,163 restricted stock units and the 11,279 stock options is contingent upon Director Michael J. Yang's continuous service with Pacira BioSciences, Inc. through the vesting date of June 11, 2026.

Future Outlook

The vesting of both the restricted stock units and stock options on June 11, 2026, is contingent upon Director Michael J. Yang's continuous service with Pacira BioSciences, Inc., indicating an expectation of his continued role within the company.

Industry Context

The grant of restricted stock units and stock options to a director is a common practice in the biotechnology and pharmaceutical industry, serving as a key component of executive and director compensation packages designed to align leadership interests with long-term shareholder value creation and retention.

Comparison to Industry Standards

• While specific comparable companies or projects are not detailed in this filing, the use of restricted stock units and stock options as a form of director compensation is a widely adopted practice across the biotechnology and pharmaceutical sectors, consistent with industry standards for incentivizing long-term commitment and performance.

Corporate Governance

Related Party Transactions

• Grant of 6,163 restricted stock units and 11,279 stock options to Michael J. Yang, a Director of Pacira BioSciences, Inc., as part of his compensation.

Stakeholder Impact

• Shareholders: The equity grants align the interests of Director Michael J. Yang with those of shareholders, incentivizing long-term value creation and retention of key leadership.
• Employees (specifically Director): Michael J. Yang receives significant equity compensation, contingent on his continued service, which serves as a retention and performance incentive.

Next Steps

• Vesting of 6,163 restricted stock units on June 11, 2026, contingent on continuous service.
• Vesting and exercisability of 11,279 stock options on June 11, 2026, contingent on continuous service.

Key Dates

Keywords

Pacira BioSciences, PCRX, SEC Form 4, Insider Trading, Beneficial Ownership, Restricted Stock Units, Stock Options, Director Compensation, Equity Grant, Rule 10b5-1